Browsing by Author Thompson, Alexander

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2012C-reactive protein, fibrinogen, and cardiovascular disease predictionWoodward, Mark; Caslake, Muriel; Di Angelantonio, Emanuele; et al, Various; Gao, Pei; Kaptoge, Stephen; Pennells, Lisa; Sarwar, Nadeem; Thompson, Alexander; Walker, Matthew; White, Ian; Wood, Angela; The George Institute for Global HealthC-reactive protein, fibrinogen, and cardiovascular disease prediction, The New England Journal of Medicine, vol.367, 14, 2012,pp 1310-1320
2014Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studiesBooth, David; George, Jacob; McCaughan, Geoffrey William; Bollipo, Steven; Cheng, Wendy; Crawford, Darrell; Dore, Gregory; Leung, Reynold; Mitchell, Joanne; Ostapowicz, George; Roberts, Stuart; Sievert, William; Sloss, Andrew; Thompson, Alexander; Weltman, Martin; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Centenary InstituteDistribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies, Journal of Gastroenterology and Hepatology, vol.29, 1, 2014,pp 179-184
2017Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapyGeorge, Jacob; Strasser, Simone; Desmond, Paul; et al, Various; Lee, Alice; Lim, Lucy; Nicoll, Amanda J.; Patterson, Scott; Roberts, Stuart; Sievert, William; Thompson, Alexander; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: MedicineFive-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy, Liver International, vol.37, 6, 2017,pp 827-835
2012New Horizons: IL28, Direct-acting Antiviral Therapy for HCVMcCaughan, Geoffrey William; McHutchison, John; Thompson, Alexander; Central Clinical School: Centenary InstituteNew Horizons: IL28, Direct-acting Antiviral Therapy for HCV in Advanced Therapy for Hepatitis C, Wiley-Blackwell Publishing, 2012, pp. 196-213
2016Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studiesHaber, Paul; Applegate, Tanya; Dore, Gregory J.; Grebely, Jason; Hellard, Margaret; Iser, David M.; Lloyd, Andrew; Maire, Laurence; Martinello, Marianne; Matthews, Gail; Petoumenos, Kathy; Sasadeusz, J; Shaw, David R; Thompson, Alexander; Yeung, Barbara; Central Clinical School: Addiction MedicineShort duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies, Antiviral Therapy, vol.21, 5, 2016,pp 425-434
2016Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studiesHaber, Paul; Applegate, Tanya; Dore, Gregory J.; Grebely, Jason; Hellard, Margaret; Iser, David M.; Lloyd, Andrew; Maire, Laurence; Martinello, Marianne; Matthews, Gail; Petoumenos, Kathy; Sasadeusz, J; Shaw, David R; Thompson, Alexander; Yeung, Barbara; Central Clinical School: Addiction MedicineShort duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies, Antiviral Therapy, vol.21, 5, 2016,pp 425-434